IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11814381 B1

PDFFull Text
Date of Patent:
Nov. 14, 2023

Filed:

Oct. 07, 2020

Pyrazolopyridine derivative having glp-1 receptor agonist effect

Applicant:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Inventors:

Hitoshi Yoshino, Shizuoka, JP;

Satoshi Tsuchiya, Shizuoka, JP;

Atsushi Matsuo, Shizuoka, JP;

Tsutomu Sato, Shizuoka, JP;

Masahiro Nishimoto, Shizuoka, JP;

Kyoko Oguri, Shizuoka, JP;

Hiroko Ogawa, Shizuoka, JP;

Yoshikazu Nishimura, Shizuoka, JP;

Yoshiyuki Furuta, Kanagawa, JP;

Hirotaka Kashiwagi, Shizuoka, JP;

Nobuyuki Hori, Shizuoka, JP;

Takuma Kamon, Shizuoka, JP;

Takuya Shiraishi, Shizuoka, JP;

Shoshin Yoshida, Shizuoka, JP;

Takahiro Kawai, Shizuoka, JP;

Satoshi Tanida, Shizuoka, JP;

Masahide Aoki, Shizuoka, JP;

Assignee:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Attorney:

Yong Zhao

Primary Examiner:

Brenda L Coleman

Int. Cl.
CPC ...
A61K 31/437 (2006.01); A61P 1/16 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C07D 471/04 (2006.01); A61K 31/506 (2006.01); C07D 519/00 (2006.01); A61K 31/4725 (2006.01); A61K 31/444 (2006.01); A61K 31/496 (2006.01); A61K 31/5386 (2006.01); A61K 31/5377 (2006.01); A61K 31/4709 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); A61P 1/16 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); C07D 519/00 (2013.01);
Abstract

The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

Find Patent Forward Citations

Loading…